Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643847 | 1.00 | DPP4 (0.50) | DPP4GAATSHRAGTR1HTR2A | |
| SCHEMBL1643851 | 1.00 | DPP4 (0.50) | DPP4GAATSHRAGTR1HTR2A | |
| SCHEMBL3748591 | 1.00 | DPP4 (0.50) | DPP4GAATSHRAGTR1HTR2A | |
| SCHEMBL16211980 | 0.89 | HTR2A (0.53) | DPP4GAATSHRAGTR1HTR2A | |
| SCHEMBL22437509 | 0.89 | HTR2A (0.53) | DPP4GAATSHRAGTR1HTR2A | |
| SCHEMBL29023696 | 0.89 | HTR2A (0.53) | DPP4GAATSHRAGTR1HTR2A | |
| SCHEMBL29457652 | 0.89 | HTR2A (0.53) | DPP4GAATSHRAGTR1HTR2A | |
| SCHEMBL16372470 | 0.89 | HTR2A (0.53) | DPP4GAATSHRAGTR1HTR2A | |
| SCHEMBL29023699 | 0.89 | HTR2A (0.53) | DPP4GAATSHRAGTR1HTR2A | |
| Hydrochloric Acid SCHEMBL16372240 | 0.87 | HTR2A (0.56) | DPP4GAATSHRAGTR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4666533-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| US-7411093-B2 | Aminocycloalkanes as DPP-IV inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-08-12 | — | — | US | claimed |
| JP-2008524279-A | — | — | 2008-07-10 | — | — | JP | claimed |
| EP-1833782-A1 | CYCLOALKYLAMINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-09-19 | — | — | EP | claimed |
| WO-2006066770-A1 | CYCLOALKYLAMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | claimed |
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | US | claimed |
| EP-1919854-B1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBVIE INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-7834012-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| EP-1833782-B1 | CYCLOALKYLAMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-7411093-B2 | Aminocycloalkanes as DPP-IV inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-08-12 | — | — | US | disclosed |
| EP-1833782-A1 | CYCLOALKYLAMINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-09-19 | — | — | EP | disclosed |
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
| WO-2006066770-A1 | CYCLOALKYLAMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | DPP4, DPP7, DPP3 | DPP4 1/4885GAA 644/4885TSHR 1719/4885 |
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885GAA 128/4885TSHR 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.